We’re proud to announce that our first paper of the year has been published! “Therapeutic antagonism of a key toxin driving Alzheimer’s disease: Comparison of a peptide variant and small molecule.” Congratulations to all the authors involved in this important work and...
We were delighted to welcome Jo Hayman to visit Neuro-Bio to spend time with Baroness Greenfield and other members of the team. Jo met with our CEO & Founder, Baroness Susan Greenfield, for a series of discussions, including preparations for a panel event...
A brilliant and energising exchange of ideas this week as Baroness Greenfield (CEO) and Dr Sara Garcia Ratés (CSO) met with the Dalloway Partners team – Vanessa Collomar, Helen James and Ella Mamelok. We were proud to share the Neuro-Bio team’s vision and 3-year...
We were extremely excited and proud to see our Founder and CEO, Baroness Susan Greenfield, in Milan last week for a series of productive meetings with prospective investors and collaborators, including a very exciting visit to San Raffaele Hospital! During the visit...
Neuro-Bio’s Founder & CEO Baroness Susan Greenfield was interviewed by Danilo di Diodoro, medical journalist and psychiatrist, highlighting our research into the T14 peptide and its potential role in the earliest stages of Alzheimer’s disease. As the field...
The event is hosted at the Leonardo Royal Hotel in Oxford on Thursday 5th February. BioWales Oxford brings together leaders from industry, academia, and investment to strengthen collaboration between the Welsh and Oxford life sciences ecosystems. The event provides an...
